Emerging retatrutide, a dual -action medication targeting equally GLP-1 and GIP receptors, is generating considerable buzz within the weight loss community. Initial clinical trials have shown substantial decreases in physical size and improvements in physiological markers for individuals with obesity . Scientists believe this novel approach coul… Read More